ANIP vs IMVT
ANIP: A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions. IMVT: Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by pathogenic IgG antibodies.
Side-by-side fundamentals
| Metric | ANIP | IMVT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $78.37 | $38.62 | |
| Market cap as of 2026-08-04 | $1.9B | $7.9B | |
| P/E as of 2026-08-04 | 19.76 | n/a | |
| PEG as of 2026-08-04 | 1.13 | -11.68 | IMVT lower |
| Net margin as of 2026-08-04 | +10.0% | n/a | |
| Gross margin as of 2026-08-04 | +60.8% | n/a | |
| Operating margin as of 2026-08-04 | +13.4% | n/a | |
| ROE as of 2026-08-04 | +17.8% | -68.2% | ANIP higher |
| ROA as of 2026-08-04 | +6.6% | -62.2% | ANIP higher |
| Debt / equity as of 2026-08-04 | 1.09 | 0.00 | IMVT lower |
| Revenue growth (YoY) as of 2026-08-04 | +37.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +40.8% | n/a | |
| Dividend yield as of 2026-08-04 | +0.0% | n/a | |
| Beta as of 2026-08-04 | 0.47 | 1.19 | |
| 1-year return as of 2026-07-27 close | +16.1% | +140.2% | IMVT higher |
Fundamentals: market data, as of 2026-08-04. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.